PL377858A1 - Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków - Google Patents

Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Info

Publication number
PL377858A1
PL377858A1 PL377858A PL37785804A PL377858A1 PL 377858 A1 PL377858 A1 PL 377858A1 PL 377858 A PL377858 A PL 377858A PL 37785804 A PL37785804 A PL 37785804A PL 377858 A1 PL377858 A1 PL 377858A1
Authority
PL
Poland
Prior art keywords
methyl
phenyl
paroxetine
trifluoro
anxiety
Prior art date
Application number
PL377858A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL377858A1 publication Critical patent/PL377858A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL377858A 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków PL377858A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments

Publications (1)

Publication Number Publication Date
PL377858A1 true PL377858A1 (pl) 2006-02-20

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377858A PL377858A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluoro-2-metylo-fenylo)-etylo]-metyloamidu kwasu 2-(S)-(4-fluoro-2-metylofenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków
PL377857A PL377857A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL377857A PL377857A1 (pl) 2003-04-17 2004-04-16 Kombinacje paroksetyny i [1-(R)-(3,5-bis-trifluorometylo-fenylo)-etylo]-metyloamidu kwasu 4-(S)-(4-acetylo-piperazyn-1-ylo)-2-(R)-(4-fluoro-2-metylo-fenylo)-piperydyno-1-karboksylowego do leczenia depresji i/albo lęków

Country Status (18)

Country Link
US (4) US20060241143A1 (pl)
EP (4) EP1653956A1 (pl)
JP (4) JP2006523651A (pl)
KR (2) KR20060003876A (pl)
CN (2) CN1809355A (pl)
AU (2) AU2004229181A1 (pl)
BR (2) BRPI0409377A (pl)
CA (2) CA2522311A1 (pl)
CO (1) CO5700753A2 (pl)
GB (1) GB0308968D0 (pl)
IS (2) IS8128A (pl)
MA (2) MA27731A1 (pl)
MX (2) MXPA05011064A (pl)
NO (2) NO20055367L (pl)
PL (2) PL377858A1 (pl)
RU (2) RU2005135647A (pl)
WO (4) WO2004091616A1 (pl)
ZA (2) ZA200508067B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
JP2003522739A (ja) * 1999-12-17 2003-07-29 シェーリング コーポレイション 選択的ニューロキニンアンタゴニスト
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1451153B1 (en) * 2001-11-13 2007-09-26 Schering Corporation Nk1 antagonists
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
GB0308968D0 (en) 2003-05-28
EP1615642A1 (en) 2006-01-18
CN1809359A (zh) 2006-07-26
JP2006523652A (ja) 2006-10-19
WO2004091617A1 (en) 2004-10-28
IS8128A (is) 2005-11-15
PL377857A1 (pl) 2006-02-20
US20060241124A1 (en) 2006-10-26
CA2522313A1 (en) 2004-10-28
CA2522311A1 (en) 2004-10-28
MXPA05011064A (es) 2006-04-18
MA27731A1 (fr) 2006-01-02
EP1613325A1 (en) 2006-01-11
NO20055367L (no) 2005-11-14
US20060217395A1 (en) 2006-09-28
AU2004229181A1 (en) 2004-10-28
IS8129A (is) 2005-11-15
US20060241143A1 (en) 2006-10-26
WO2004091624A1 (en) 2004-10-28
JP2006523649A (ja) 2006-10-19
US20060287325A1 (en) 2006-12-21
EP1615641A1 (en) 2006-01-18
WO2004091616A1 (en) 2004-10-28
ZA200508067B (en) 2007-02-28
JP2006523651A (ja) 2006-10-19
CO5700753A2 (es) 2006-11-30
MA27730A1 (fr) 2006-01-02
BRPI0409379A (pt) 2006-04-25
BRPI0409377A (pt) 2006-04-25
EP1653956A1 (en) 2006-05-10
ZA200508068B (en) 2007-02-28
CN1809355A (zh) 2006-07-26
JP2006523650A (ja) 2006-10-19
KR20060003876A (ko) 2006-01-11
WO2004091615A1 (en) 2004-10-28
AU2004229179A1 (en) 2004-10-28
MXPA05011063A (es) 2005-12-12
RU2005135647A (ru) 2006-06-10
KR20060003875A (ko) 2006-01-11
NO20055368L (no) 2005-11-14
RU2005135649A (ru) 2006-03-20

Similar Documents

Publication Publication Date Title
EP1620095A4 (en) HEMMER OF ACT ACTIVITY
IL188207A (en) 1 - [2 - (3-Tret-Butyl Oreido) -3,3-Dimethylbutyril] -4- (7-Methoxy-2-Pyrazole-1-Il-Quinoline-4-Oxyl) -Pyrrolidine-Carboxylic Acid (1 -Cyclopropylamino oxalibutyl) affluent and uses
HUP0302647A3 (en) Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide and their intermediates
EP1784175A4 (en) INHIBITORS OF ACT ACTIVITY
EP1737861A4 (en) HEMMER OF ACT ACTIVITY
AU2003243420A8 (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
SI2937341T1 (sl) Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
ATE361279T1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamidderivat , verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP1453382A4 (en) METHOD AND COMPOSITIONS FOR CORRECTING CROSS-BREAKDOWN OF THE HEART
IL157319A0 (en) Catheter and method for mapping purkinje fibers
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
AU2003293405A8 (en) Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
DE60300021D1 (de) (S)-4-Amino-5-Chloro-2-Methoxy-N-[1-[1-(2-Tetrahydrofuryl-Carbonyl)-4-Piperidinylmethyl]-4-Piperidinyl]benzamid zur Behandlung von Magen-Darmbewegungskrankheiten
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
IL184059A0 (en) Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexylphenyl]piperazine
AU2003303287A8 (en) Method of cardiac risk assessment
PL373946A1 (pl) Fenoksy-piperydyny do leczenia chorób takich jak schizofrenia i depresja
EP1567183A4 (en) METHOD AND COMPOSITIONS FOR TREATING OTITIS MEDIA
EP1461090A4 (en) COMPOSITIONS AND METHODS OF TREATING OTITIS MEDIA
EP1487443A4 (en) HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES
AU2003278806A1 (en) Composition and method for moisturizing nasal tissue
EP1554033A4 (en) IMPROVED COMPOSITIONS FOR REMOVING BORED BEADS OF SEMICONDUCTOR LOADING BUFFER COATINGS AND METHOD FOR THEIR USE

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)